马瓦卡门维护剂量确定:对高伤性心肌病的个性化治疗的见解
Smita Scholtz1, Cédric Coppée2, Kawa Mohemed2
1Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany sscholtz@hdz-nrw.de.
马瓦卡门因减少左心室外流通道 (LVOT) 阻塞和改善症状而有效治疗阻塞性多变性心肌病 (oHCM). 基于CYP2C19状态和心声回应的个性化剂量确保了安全性,并优化了患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 药物基因组学 药物基因组学
- 临床治疗学 临床治疗学
背景情况:
- 阻塞性缩性心肌病 (oHCM) 具有超收缩性和左心室外流通道 (LVOT) 阻塞的特征.
- 马瓦卡门是首个批准的针对这些机制的肌肉酶抑制剂.
研究的目的:
- 评估在患有症状的oHCM的患者中mavacamten的实际有效性和安全性.
- 评估确定维护剂量以优化个人治疗的过程.
主要方法:
- 对36名有症状的oHCM患者的分析完成了 mavacamten 启动.
- 在基线和3个月内评估心声学参数 (LVOT梯度,LVEF) 和生物标志物 (NT-proBNP,热素I).
- 用NYHA类和KCCQ分数评估临床状态,并对代谢状态进行CYP2C19遗传测试.
主要成果:
- 在休息和引起的LVOT梯度显著减少 (p<0.001).
- 改善了心脏生物标志物 (NT-proBNP,Troponin I) 和扩张功能.
- 在NYHA类和KCCQ得分中显著的临床改善,轻微的LVEF下降 (p=0.0004).
- 超过50%的患者需要调整剂量,以便在14周内达到维持水平.
结论:
- 马瓦卡门开始治疗对于有症状的oHCM是安全有效的.
- CYP2C19代谢状态指导初始剂量,而心声回应则告知个体剂量调整的安全性.
- 现实世界的数据支持个人化Mavacamten疗法用于oHCM管理.
更多相关视频
08:51Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
Published on: November 11, 2022
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
相关概念视频
Dosage Regimen: Individualization
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
